The DOI matches its Crossref record; the references it cites are not checked yet.
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
Open accessAbstract
Prolyl‐tRNA synthetase 1 (PARS1) has attracted much interest in controlling pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases. However, there are concerns about its catalytic inhibition for potential adverse effects on global protein synthesis. We developed a novel compound, DWN12088, whose safety was validated by clinical phase 1 studies, and therapeutic efficacy was shown in idiopathic pulmonary fibrosis model. Structural and kinetic analyses revealed that DWN12088 binds to catalytic site of each protomer of PARS1 dimer in an asymmetric mode with different affinity, resulting in decreased responsiveness at higher doses, thereby expanding safety window. The mutations disrupting PARS1 homodimerization restored the sensitivity to DWN12088, validating negative communication between PARS1 promoters for the DWN12088 binding. Thus, this work suggests that DWN12088, an asymmetric catalytic inhibitor of PARS1 as a novel therapeutic agent against fibrosis with enhanced safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










![Figure 6 Effect of PARS1 dimeric interaction on the efficacy and toxicity of HF and DWN12088 A The role of F1097, E1123 and R1152 in the binding to the compounds, ATP and proline in complex structures of PARS1‐HF‐ANP (PDB: 4HVC), PARS1‐DWN12088‐ATP and PARS1‐proline (PDB: 4K87). The color codes of the structures are the same as those shown in Fig 3A and B.B The binding of HF and DWN12088 to in vitro purified PARS1 WT and F1097A/E1123A/R1152L (FA/EA/RL) mutant was determined via microscale thermophoresis (MST). Kd values are listed in the top left part of the graph (technical replicates n = 3; mean ± SD).C Catalytic activities of PARS1 WT and FA/EA/RL mutant were determined by prolylation assay in the presence of [3H]proline. To monitor the effect of PARS1 RA/EA/RL mutant on the activity of PARS1 WT, the same concentrations of the proteins were pre‐incubated for 10 min and then used for the assay. The formation of Pro‐tRNAPro was measured using liquid scintillation counter (technical replicates n = 3; mean ± SEM).D The kinetic values of PARS1 with homodimer (WT/WT) and heterodimer (WT/MT) settings were determined by prolylation assay in the presence of [3H]proline. MT, PARS1 FA/EA/RL (biological replicates n ≥ 3; mean ± SEM).E 293 T cells were transfected with the indicated plasmid DNAs for 24 h. The cell lysates were prepared and pulled down with Strep bead for 2 h. Co‐precipitated proteins were determined by immunoblot assay. WT, PARS1 wild type; MT, PARS1 FA/EA/RL.F Schematic representation of the strategy for generating a monomer‐like EPRS1. Endogenous EPRS1 dimer would function as a monomer‐like EPRS1 by forming a dimer with exogenous PARS1 mutant that cannot bind to the compounds and does not show the catalytic activity.G, H WI‐26 VA4 cells stably expressing each of EV (empty vector) or PARS1 FA/EA/RL mutant were incubated with the indicated compounds for 72 h. Dose–response curves of the compounds for collagen levels and cytotoxicity were determined and relative ratio of CC50 to the IC50 of collagen for HF (G) and DWN12088 (H) were calculated. The IC50 values were calculated using GraphPad Prism 7.0 (collagen ELISA, n = 12 from four independent experiments (triplicate for each experiment); cytotoxicity assay, n = 8 from four independent experiments (duplicate for each experiment); Welch's t test; ***P < 0.001; mean ± SEM).I, J Relative slopes of dose–response curves of HF (I) and DWN12088 (J) for collagen levels were determined in cells stably expressing each of EV or PARS1 FA/EA/RL mutant. The slopes were determined by using GraphPad Prism 7.0 (n = 3 in triplicates for collagen ELISA, n = 4 in duplicates for cytotoxicity assay; mean ± SEM; Welch's t test; ***P < 0.001; mean ± SEM).K WI‐26 VA4 cells stably expressing each of EV or PARS1 FA/EA/RL mutant were incubated with the indicated compounds in the presence of TGF‐β for 72 h. The levels of the indicated proteins were determined by immunoblotting. The percentage of proline in polypeptide sequences is shown on the right side of immunoblot images. Source data are available online for this figure.](https://figures.cochat.ai/paper-figures/a55e69d5d29a401cadac7cb483df15a2/control-of-fibrosis-with-enhanced-safety-via-asymmetric-inhibition-of-prolyltrna-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The statistical analysis was performed accounting for the relatively high drug related withdrawals (23%) [129].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [129]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The effect is accentuated to +47 mL (90% CI −108, +203 mL) at 24 weeks (n=27) and +235 mL (90% CI +8, +389), normalized, at 36 weeks (n=19) if only the observed FVC is analyzed [129].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [129]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Important secondary endpoints included reduction of plasma levels of TGF-β1 by 57% (21.3 ± 5 to 7.1 ± 1.5 ng/mL) and elevation in matrix metalloproteinase 13 (MMP-13) levels by 67% (P=0.01) compared to baseline [129].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [129]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The AIR study is a phase 2 trial (NCT04533022) of 46 patients with treatment naïve IPF who were given placebo or buloxibutid 100 mg twice daily with results demonstrating a change from baseline in FVC of −50 mL (90% CI −150, +50) at 24 weeks and +13 mL (90% CI −69, +96), normalized, at 36 weeks [129].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 58 · Cited by 22
Metadata
- Authors
- Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., Park, S., Kim, S., Cho, S. H., Park, S., Bang, K., Seo, M., Kim, J. H., Lee, B., Park, J. S., Hwang, K. Y., & Kim, S.
- Affiliations
- Yonsei University (KR)
- Daewoong Pharmaceutical (South Korea) (KR)
- Korea University (KR)
- Corresponding author
- Hwang, Kwang Yeon
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2023-05-22
- Volume
- 15
- Issue
- 7
- Pages
- e16940-e16940
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC10331583
- OpenAlex
- W4377220482
- Cited by
- 22
- References
- 58
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 5 · 2023: 3
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Korea Drug Development Fund (KDDF‐201812‐20)
- Ministry of Science and ICT, South Korea (2021R1A3B1076605, 2020R1A2C2005670, 2021R1C1C1013332)
- Yonsei University (2020‐22‐0358, 2020‐22‐0356, 2021‐22‐0061)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, fibrosis, collagen deposition, drug safety, homodimerization, protein synthesis
- MeSH terms
- Amino Acyl-tRNA Synthetases, Fibrosis, Humans, Proline, Protein Biosynthesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. https://app.cochat.ai/papers/10.15252/emmm.202216940
- The paper
- Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., Park, S., Kim, S., Cho, S. H., Park, S., Bang, K., Seo, M., Kim, J. H., Lee, B., Park, J. S., . . . Kim, S. (2023). Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.